LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Joint Statement on HE and Partnerships

23/11/2018
POSITION PAPER

Joint Statement on HorizonEurope and Partnerships

The six undersigned European health industry associations are ambitious about a healthier future for the European citizens, based on medical innovation, timely access to quality health interventions, better health outcomes for patients, and affordable healthcare. Horizon Europe has a key role to play in that future.

At their meeting on 30 November 2018, we encourage the Competitiveness Council to adopt a position on the Horizon Europe framework, including list of missions and partnerships, and to support the creation of a public-private partnership focused on healthcare innovation.

This positive decision will enable timely completion of the legislative process and start of Horizon Europe and its instruments, which directly support patient access to innovative healthcare solutions, Europe’s cohesion and growth, as well as the continuing attractiveness of Europe as a place for research-intensive industries and investments.

Along with our member companies and national associations, we represent a vibrant and connected research and innovation ecosystem and are committed to working together, and in partnership with all stakeholders, to ensure that Europe continues to be at the forefront of healthcare innovation for the benefit of patients. A thriving environment that enables research, innovation and deployment is essential for highly research-intensive health sectors, and for economic growth in Europe.

We therefore support the ambitions of Horizon Europe based on excellence and impact that will enhance Europe’s competitiveness in the world and of its Health Cluster with six interconnected and complementary themes. We believe that an institutional cross-sectorial public-private partnership for health research and innovation that builds on lessons from existing joint undertakings will be an important tool to achieve the Health Cluster’s ambitious goals: to increase Europe’s translational research capabilities, deliver solutions for the patients, and contribute to making our healthcare systems fit for tomorrow.

We look forward to remaining constructive partners in discussions on this important issue and urge Member States to continue joint efforts for moving the Horizon Europe legislation forward and enable the start of the programme in 2021.

COCIR: European Coordination Committee of the Radiological, Electromedical and Healthcare IT industry, www.cocir.org
EBE: Emerging Biopharmaceutical Enterprises, https://www.ebe-biopharma.eu/
EFPIA: European Federation of Pharmaceutical Industries and Associations, www.efpia.eu
EuropaBio: European Associations for Bioindustries, https://www.europabio.org/
MedTech Europe: European Association of medical technology industries comprising medical devices, diagnostics and digital health. http://www.medtecheurope.org
Vaccines Europe: https://www.vaccineseurope.eu

Download the file below to read the full Position Paper.

Joint Statement on HE and Partnerships


Download
2018_11_H_PP_Joint-Statement-on-HE-and-PartnershipsDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

11/07/2025

Industrial Decarbonisation Accelerator Act – EuropaBio Position


Read more
07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more

Important links

  • Industrial Decarbonisation Accelerator Act – EuropaBio Position
  • EuropaBio Position on the Critical Medicines Act

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.